neoX Biotech secures multimillion-dollar investment from Vision Plus, Sequoia, and Morningside

Beijing neoX Biotech today announced the completion of a 10 million dollars Pre-A round, jointly led by Vision Plus Capital and Sequoia Capital China. Existing investor Morningside Venture Capital also participated.

Beijing neoX Biotech today announced the completion of a 10 million dollars Pre-A round, jointly led by Vision Plus Capital and Sequoia Capital China. Existing investor Morningside Venture Capital also participated.

Proceeds from the round will be mainly used for team construction, expansion of high-throughput laboratory, and advancing the cooperation in development of drug pipelines.

neoX Biotech is a high-tech pharmaceutical company engaged in early-stage drug developmentbased on AI and computational biophysical technology. It focuses on the research and development of macromolecular drugs, especially in the field of immuno-oncology.

neoX Biotech had previously received millions of dollars in an angel round from Morningside Venture Capital and Zhen Fund.

neoX has developed a sophisticated platform for early discovery of therapeutics by characterizing protein-protein interactions (PPI). The company has established cooperation with biomedical companies globally such as Merck and BioDuro to accelerate drug R&D pipelines.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/07/09/neox-biotech-secures-multimillion-dollar-investment-from-vision-plus-sequoia-and-morningside/.

Leave a Reply

Please Login to Comment